Media Kits

Lilly's Quest for COVID-19 Treatments

Read More About Our COVID-19 Research

Cyramza® (ramucirumab) Approved by the U.S. FDA as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Read More About Cyramza

Retevmo™ (selpercatinib): First Therapy Specifically for Patients with Advanced RET-Driven Cancers Is Approved

Read More About Retevmo

woman teaching a girl to ride a bike

Reyvow™ (lasmiditan) C-V: A First-in-Class Acute Treatment for Migraine Is Now Available

Read More About Reyvow